AIM
AZN icon

Acrospire Investment Management’s AstraZeneca AZN Stock Holding History

Acrospire Investment Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-53
Closed -$4K – 139
2017
Q2 		$4K Sell
53
-250
-83% -$16.3K ﹤0.01% 1982
2017
Q1 		$19K Buy
+303
New +$17.6K 0.02% 1648
2016
Q4 		– Sell
-1,803
Closed -$118K – 2196
2016
Q3 		$118K Buy
1,803
+1,650
+1,078% +$108K 0.08% 414
2016
Q2 		$9K Buy
+153
New +$8.89K 0.01% 1767

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acrospire Investment Management's AZN Position: Q3 2017 in Review

Acrospire Investment Management sold out of AstraZeneca (AZN) in Q3 2017, closing a stake of 53 shares — an estimated $4K sold.

Acrospire Investment Management first reported a position in AZN in Q2 2016 and held it in 4 quarters. The position peaked at $118K in Q3 2016. 454 funds tracked by Wall St. Rank hold AZN as of Q3 2017.

  • Acrospire Investment Management reported no remaining AstraZeneca position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 53 AstraZeneca shares in Q3 2017, an estimated $4K.
  • Acrospire Investment Management first reported a position in AstraZeneca in Q2 2016 and held it in 4 quarters.
  • Acrospire Investment Management's AstraZeneca position peaked at $118K in Q3 2016.
  • 454 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.